The Medicines Company of Parsippany, N.J., has received approval for its IV-administered Cleviprex (clevidipine butyrate) injectable emulsion for reducing BP when oral treatment is neither feasible nor desirable.
A novel IV antihypertensive, Cleviprex is an advance over currently available drugs, providing rapid and precise BP control in the critical-care setting.
“With the approval of Cleviprex, physicians have a new treatment option for intensive control of blood pressure that may advance the standard of care in the operating room, the ICU, and the emergency department,” said Robert Califf, MD, professor of medicine and vice chancellor for research at Duke University in Durham, N.C.
Rapid in both onset and offset of action, Cleviprex can be titrated for precise BP control. Unlike many IV antihypertensives, Cleviprex is metabolized in blood and tissues rather than the kidney or liver and does not accumulate in the body.